HMGB1 as an autocrine stimulus in human T98G glioblastoma cells: Role in cell growth and migration

Journal of Neuro-Oncology

Volumn 87, Issue 1, 2008, Pages 23-33

  Bassi, Rosaria ^a   Giussani, Paola ^a   Anelli, Viviana ^a   Colleoni, Thomas ^a   Pedrazzi, Marco ^b   Patrone, Mauro ^c   Viani, Paola ^a   Sparatore, Bianca ^b   Melloni, Edon ^b   Riboni, Laura ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

ERK1 2; HMGB1; Human gliomas; Motility; Necrotic death; Proliferation; Rac1; RAGE

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ANTIMITOTIC AGENT; HIGH MOBILITY GROUP B1 PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; RAC1 PROTEIN;

ARTICLE; AUTOCRINE EFFECT; CANCER GROWTH; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL SECRETION; CONTROLLED STUDY; DNA REPLICATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; METASTASIS; NECROSIS; PROTEIN FUNCTION; PROTEIN INTERACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANTIGENS, NEOPLASM; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; GLIOBLASTOMA; HMGB1 PROTEIN; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; NECROSIS; SIGNAL TRANSDUCTION;

EID: 38649103181     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-007-9488-y     Document Type: Article

References (49)

1. Lotze MT, Tracey KJ (2005) High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 5:331-342
2. Müller S, Ronfani L, Bianchi ME (2004) Regulated expression and subcellular localization of HMGB1, a chromatin protein with a cytokine function. J Intern Med 255:332-343
3. Yang H, Wang H, Czura CJ, Tracey KJ (2005) The cytokine activity of HMGB1. J Leukoc Biol 78:1-8
4. Ulloa L, Messmer D (2006) High-mobility group box 1 (HMGB1) protein: friend and foe. Cytokine Growth Factor Rev 17:189-201
5. Bianchi ME (2004) Significant (re)location: How to use chromatin and/or abundant proteins as messages of life and death. Trends Cell Biol 14:287-293
6. Erlandsson Harris H, Andersson U (2004) The nuclear protein HMGB1 as a proinflammatory mediator. Eur J Immunol 34:1503-1512
7. Wang H, Yang H, Tracey KJ (2004) Extracellular role of HMGB1 in inflammation and sepsis. J Intern Med 255:320-331
8. Raucci A, Palumbo R, Bianchi ME (2007) HMGB1: A signal of necrosis. Autoimmunity 40:285-289
9. Bierhaus A, Humpert PM, Morcos M, Wendt T, Chavakis T, Arnold B, Stern DM, Nawroth PP (2005) Understanding RAGE, the receptor for advanced glycation end products. J Mol Med 83:876-886
10. Huttunen HJ, Rauvala H (2004) Amphoterin as an extracellular regulator of cell motility: From discovery to disease. J Intern Med 255:351-366
11. Ellerman JE, Brown CK, de Vera M, Zeh HJ, Billiar T, Rubartelli A, Lotze MT (2007) Masquerader: High mobility group box-1 and cancer. Clin Cancer Res 13:2836-2848
12. Kuniyasu H, Chihara Y, Takahashi T (2003) Co-expression of receptor for advanced glycation end products and the ligand amphoterin associates closely with metastasis of colorectal cancer. Oncol Rep 10:445-448
13. Huttunen HJ, Fages C, Kuja-Panula J, Ridley AJ, Rauvala H (2002) Receptor for advanced glycation end products-binding COOH-terminal motif of amphoterin inhibits invasive migration and metastasis. Cancer Res 62:4805-4811
14. Bartling B, Hofmann HS, Weigle B, Silber RE, Simm A (2005) Down-regulation of the receptor for advanced glycation end-products (RAGE) supports non-small cell lung carcinoma. Carcinogenesis 26:293-301
15. Riuzzi F, Sorci G, Donato R (2006) The amphoterin (HMGB1)/receptor for advanced glycation end products (RAGE) pair modulates myoblast proliferation, apoptosis, adhesiveness, migration, and invasiveness. Functional inactivation of RAGE in L6 myoblasts results in tumor formation in vivo. J Biol Chem 281:8242-8253
16. Lotze MT, DeMarco RA (2003) Dealing with death: HMGB1 as a novel target for cancer therapy. Curr Opin Investig Drugs 4:1405-1409
17. Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, Cavenee WK (2002) The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 61:215-225
18. Tysnes BB, Mahesparan R (2001) Biological mechanisms of glioma invasion and potential therapeutic targets. J Neurooncol 53:129-147
19. Hulleman E, Helin K (2005) Molecular mechanisms in gliomagenesis. Adv Cancer Res 94:1-27
20. Sparatore B, Passalacqua M, Patrone M, Melloni E, Pontremoli S (1996) Extracellular high-mobility group 1 protein is essential for erythroleukaemia cell differentiation. Biochem J 320:253-256
21. Sparatore B, Patrone M, Passalacqua M, Pedrazzi M, Ledda S, Pontremoli S, Melloni E (2005) Activation of A431 human carcinoma cell motility by extracellular high-mobility group box 1 protein and epidermal growth factor stimuli. Biochem J 389:215-221
22. Riboni L, Viani P, Bassi R, Giussani P, Tettamanti G (2001) Basic fibroblast growth factor-induced proliferation of primary astrocytes. J Biol Chem 276:12797-12804
23. Bassi R, Anelli V, Giussani P, Tettamanti G, Viani P, Riboni L (2006) Sphingosine-1-phosphate is released by cerebellar astrocytes in response to bFGF and induces astrocyte proliferation through Gi-protein-coupled receptors. Glia 53:621-630
24. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275
25. Rubinfeld H, Seger R (2005) The ERK cascade: A prototype of MAPK signaling. Mol Biotechnol 31:151-174
26. Wallace EM, Lyssikatos JP, Yeh T, Winkler JD, Koch K (2005) Progress towards therapeutic small molecule MEK inhibitors for use in cancer therapy. Curr Top Med Chem 5:215-229
27. Taguchi A, Blood DC, Del Toro G et al (2000) Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 405:354-360
28. Salhia B, Tran NL, Symons M, Winkles JA, Rutka JT, Berens ME (2006) Molecular pathways triggering glioma cell invasion. Expert Rev Mol Diagn 6:613-626
29. Scaffidi P, Misteli T, Bianchi ME (2002) Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418:191-195
30. Bianchi ME, Manfredi A (2004) Chromatin and cell death. Biochim Biophys Acta 1677:181-186
31. Mimeault M (2002) New advances on structural and biological functions of ceramide in apoptotic/necrotic cell death and cancer. FEBS Lett 530:9-16
32. Ogretmen B, Hannun YA (2004) Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer 4:604-616
33. Mochizuki T, Asai A, Saito N, Tanaka S, Katagiri H, Asano T, Nakane M, Tamura A, Kuchino Y, Kitanaka C, Kirino T (2002) Akt protein kinase inhibits non-apoptotic programmed cell death induced by ceramide. J Biol Chem 277:2790-2797
34. Meloche S, Pouysségur J (2007) The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition. Oncogene 26:3227-3239
35. Sanson M, Thillet J, Hoang-Xuan K (2004) Molecular changes in gliomas. Curr Opin Oncol 16:607-613
36. Ishihara K, Tsutsumi K, Kawane S, Nakajima M, Kasaoka T (2003) The receptor for advanced glycation end-products (RAGE) directly binds to ERK by a D-domain-like docking site. FEBS Lett 550:107-113
37. Giese A, Loo MA, Tran N, Haskett D, Coons SW, Berens ME (1996) Dichotomy of astrocytoma migration and proliferation. Int J Cancer 67:275-282
38. Fages C, Nolo R, Huttunen HJ, Eskelinen E, Rauvala H (2000) Regulation of cell migration by amphoterin. J Cell Sci 113:611-620
39. Qiu RG, Chen J, Kirn D, McCormick F, Symons M (1995) An essential role for Rac in Ras transformation. Nature 374:457-459
40. Chan AY, Coniglio SJ, Chuang YY, Michaelson D, Knaus UG, Philips MR, Symons M (2005) Roles of the Rac1 and Rac3 GTPases in human tumor cell invasion. Oncogene 24:7821-7829
41. Chuang YY, Tran NL, Rusk N, Nakada M, Berens ME, Symons M (2004) Role of synaptojanin 2 in glioma cell migration and invasion. Cancer Res 64:8271-8275
42. Salhia B, Rutten F, Nakada M, Beaudry C, Berens M, Kwan A, Rutka JT (2005) Inhibition of Rho-kinase affects astrocytoma morphology, motility, and invasion through activation of Rac1. Cancer Res 65:8792-8800
43. Passalacqua M, Zicca A, Sparatore B, Patrone M, Melloni E, Pontremoli S (1997) Secretion and binding of HMG1 protein to the external surface of the membrane are required for murine erythroleukemia cell differentiation. FEBS Lett 400:275-279
44. Kuniyasu H, Yano S, Sasaki T, Sasahira T, Sone S, Ohmori H (2005) Colon cancer cell-derived high mobility group 1/amphoterin induces growth inhibition and apoptosis in macrophages. Am J Pathol 166:751-760
45. Wähämaa H, Vallerskog T, Qin S, Lunderius C, LaRosa G, Andersson U, Harris HE (2007) HMGB1-secreting capacity of multiple cell lineages revealed by a novel HMGB1 ELISPOT assay. J Leukoc Biol 81:129-136
46. Brezniceanu ML, Volp K, Bosser S, Solbach C, Lichter P, Joos S, Zornig M (2003) HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma. FASEB J 17:1295-1297
47. Ditsworth D, Zong WX, Thompson CB (2007) Activation of poly(ADP)-ribose polymerase (PARP-1) induces release of the pro-inflammatory mediator HMGB1 from the nucleus. J Biol Chem 282:17845-17854
48. Wharton B, McNelis U, Bell HS, Whittle IR (2000) Expression of poly(ADP-ribose) polymerase and distribution of poly(ADP-ribosyl)ation in glioblastoma and in a glioma multicellular tumour spheroid model. Neuropathol Appl Neurobiol 26:528-535
49. Raza SM, Lang FF, Aggarwal BB, Fuller GN, Wildrick DM, Sawaya R (2002) Necrosis and glioblastoma: A friend or a foe? A review and a hypothesis. Neurosurgery 51:2-12